期刊文献+

LEP,IGF-1和TNFα测定对乳腺癌患者的临床意义

Clinical Significance of Detection of Serum Leptin,Insulin-Like Growth Factor-1 and Tumor Necrosis Factor α in Breast Cancer Patients
下载PDF
导出
摘要 目的乳腺癌患者血清瘦素(LEP)、胰岛素样生长因子-1(IGF-1)、肿瘤坏死因子α(TNFα)测定的临床意义。方法用放射免疫分析法(RIA)和免疫放射分析法(IRMA)测定良性、恶性乳腺病变患者和正常对照者血清LEP,IGF-1和TNFα的浓度。结果LEP,IGF-1和TNFα的浓度在乳腺癌患者与正常对照者之间差异均有显著性。结论LEP,IGF-1和TNFα浓度测定有助于乳腺癌的诊断、治疗和研究。 Objective To research the clinical significance in the detection of serum leptin(LEP),insulin-like growth factor-1(IGF-1) and tumor necrosis factor α(TNFα) in breast cancer patients.Methods Using RIA and IRMA method to detect the serum concentrations of LEP,IGF-1,TNFα in breast cancer patient,breast benign lesion patients and normal controls.Results Serum concentrations of LEP,IGF-1,TNFα in breast cancer patient were obviously different from that of normal control group.Conclusion Detection of the serum concentrations of LEP,IGF-1,TNFα is useful for diagnosis,treating and research of breast cancer.
出处 《潍坊医学院学报》 2005年第3期188-189,共2页 Acta Academiae Medicinae Weifang
关键词 瘦素 胰岛素样生长因子-1 肿瘤坏死因子Α 乳腺癌 Leptin Insulin-like growth factor-1 Tumor necrosis factor α Breast cancer
  • 相关文献

参考文献3

  • 1Hu X, Juneja SC, Machle NJ, et al. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development [J]. J Natl Cancer lnst ,2002,94(15): 1704-1711.
  • 2Magotlin DA, Weitsman SR, Agarwal SK, et al. Leptin regulation of aromatase acttivity in adipose stromal cells from regularly cycling woman[J].Ginekol Pol,1999,70(1):1-7.
  • 3吴健民.对肿瘤标志物的再认识[J].中华检验医学杂志,2005,28(1):11-13. 被引量:116

二级参考文献18

  • 1中华医学会检验医学分会肿瘤标志物专家委员会.肿瘤标志物检测临床应用的基本原则(讨论稿)[J].中华检验医学杂志,2004,:27-27.
  • 2王健 吉强 殷建华 等.AFP实验室检测40年[A]..肿瘤标志专题讨论会论文集[C].,2002.27-35.
  • 3Pritzker KH. Cancer biomarkers : easier said than done. Clin Chem, 2002,48: 1147- 1150.
  • 4Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic. Washington DC: AACC Press,2002.20-25
  • 5Lichtenstein AV, Potapova GI. Genetic defects as tumor markers. Molecular Biol, 2003,37:159-169.
  • 6Lakhani SR, Ashworth A. Microarray and histo-pathological analysis of tumours:the future and the past? Nature Rev Cancer, 2001,1:151-157.
  • 7Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer benign breast disease and normal breast tissue. Breast Cancer Res Treat, 1996,40:171- 178.
  • 8Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 2003,3:267-275.
  • 9Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer, 2002, 2:210-219.
  • 10Sun X, Hung K, Wu L, et al. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nat Biotechol, 2002,20:186-189.

共引文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部